Table 1.
Demographic and clinical characteristics of ALL patients (n=76).
| Characteristic | |
|---|---|
| Age, years | 31.5 [15-74] |
| Gender, n (%) | |
| Male | 38 (50%) |
| Female | 38 (50%) |
| BMI, kg/m2 | 21.53 [14.88-30.49] |
| Extramedullary disease, n (%) | 14 (18.42%) |
| Number of prior chemotherapies, times | 4 [1-24] |
| Prior allogeneic HSCT, n (%) | 21 (27.63%) |
| Number of relapses, times | 1 [0-8] |
| Bone marrow tumor burden before lymphodepletion, % | 31 [0-96] |
| Pre-lymphodepletion | |
| ANC, ×109/L | 2.3 [0-9.1] |
| Hemoglobin, g/L | 99.5 [45-159] |
| Platelet count, ×109/L | 105.5 [6-412] |
| LDH, U/L | 271 [135-5268] |
| Ferritin, ng/mL | 836.9 [17.2-24458] |
| ALT, U/L | 19 [5-449] |
| AST, U/L | 21 [8-184] |
| GFR, ml/min | 122 [59-172.61] |
| Serum creatinine, μmol/L | 59.5 [34-97] |
| Serum urea, mmol/L | 4.05 [1.4-9] |
| Serum uric acid, μmol/L | 327 [89-609] |
| Targets of CAR-T cell, n (%) | |
| CD19 | 50 (65.79%) |
| CD22 | 4 (5.26%) |
| CD19-CD22 | 22 (28.95%) |
| PHT, n (%) | 19 (25%) |
| CRS, n (%) | |
| None | 14 (18.42%) |
| Grade 1 | 11 (14.47%) |
| Grade 2 | 22 (28.95%) |
| Grade 3-4 | 29 (38.16%) |
| Neurotoxicity, n (%) | 9 (11.84%) |
| Hemorrhage, n (%) | 14 (18.42%) |
| Infection, n (%) | 13 (17.11%) |
Data were described as n (%) or median [range].
ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BMI, body mass index; CRS, cytokine release syndrome; GFR, glomerular filtration rate; PHT, prolonged hematological toxicity.